Niranjan Sardesai Net Worth

The estimated Net Worth of Niranjan Sardesai is at least $382 ezer dollars as of 4 January 2017. Niranjan Sardesai owns over 9,813 units of Inovio Pharmaceuticals Inc stock worth over $381,518 and over the last 15 years Niranjan sold INO stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Niranjan Sardesai INO stock SEC Form 4 insiders trading

Niranjan has made over 6 trades of the Inovio Pharmaceuticals Inc stock since 2012, according to the Form 4 filled with the SEC. Most recently Niranjan exercised 9,813 units of INO stock worth $60,056 on 4 January 2017.

The largest trade Niranjan's ever made was exercising 33,116 units of Inovio Pharmaceuticals Inc stock on 28 August 2016 worth over $202,670. On average, Niranjan trades about 4,446 units every 89 days since 2009. As of 4 January 2017 Niranjan still owns at least 58,247 units of Inovio Pharmaceuticals Inc stock.

You can see the complete history of Niranjan Sardesai stock trades at the bottom of the page.

What's Niranjan Sardesai's mailing address?

Niranjan's mailing address filed with the SEC is 11494 SORRENTO VALLEY ROAD, , SAN DIEGO, CA, 92121.

Insiders trading at Inovio Pharmaceuticals Inc

Over the last 19 years, insiders at Inovio Pharmaceuticals Inc have traded over $23,656,819 worth of Inovio Pharmaceuticals Inc stock and bought 1,958,377 units worth $5,174,071 . The most active insiders traders include Austin W & Greenhouse David..., Jong Joseph Kim és Felix Theeuwes. On average, Inovio Pharmaceuticals Inc executives and independent directors trade stock every 22 days with the average trade being worth of $745,390. The most recent stock trade was executed by Michael John Sumner on 30 June 2024, trading 2,917 units of INO stock currently worth $19,106.

What does Inovio Pharmaceuticals Inc do?

inovio is revolutionizing the fight against cancer and infectious diseases. our immunotherapies uniquely activate best-in-class immune responses to prevent and treat disease, and have shown clinically significant efficacy with a favorable safety profile. with an expanding portfolio of immune therapies, the company is advancing a growing preclinical and clinical stage product pipeline. partners and collaborators include roche, medimmune, university of pennsylvania, darpa, drexel university, nih, hiv vaccines trial network, national cancer institute, u.s. military hiv research program, and university of manitoba. for more information, visit www.inovio.com.

Complete history of Niranjan Sardesai stock trades at Inovio Pharmaceuticals Inc

Inovio Pharmaceuticals Inc executives and stock owners

Inovio Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Jong Kim,
  President, Chief Executive Officer, Director
• Dr. J. Joseph Kim,
  CEO, Pres & Director
• Jacqueline Elizabeth Shea,
  Chief Operating Officer
• Peter Kies,
  Chief Financial Officer
• Laurent Humeau,
  Chief Scientific Officer
• Peter D. Kies,
  Chief Financial Officer
• Dr. Laurent M. Humeau,
  Chief Scientific Officer
• Dr. Jacqueline E. Shea Ph.D.,
  Chief Operating Officer
• David Weiner,
  Director
• Lota Zoth,
  Independent Director
• Simon Benito,
  Independent Chairman of the Board
• Ann Miller,
  Independent Director
• Wendy Yarno,
  Independent Director
• Jay Shepard,
  Independent Director
• Asli Gevgilili,
  Chief HR Officer
• Robert L. Crotty J.D.,
  Gen. Counsel
• Robert J. Juba Jr.,
  Sr. VP of Biological Manufacturing & Clinical Supply Management
• Dr. Jeffrey Skolnik,
  Sr. VP of Clinical Devel.
• Dr. Ami Shah Brown,
  Sr. VP of Regulatory Affairs
• Jessica C. Lee MS, MPH,
  Sr. VP of Clinical Operations & Global Integration
• E. J. Brandreth,
  Sr. VP of Quality Assurance
• Ben Matone,
  Director of Investor Relations
• Morton Collins,
  Director
• George Bickerstaff,
  Director
• Adel Mahmoud,
  Director
• Mark Bagarazzi,
  Chief Medical Officer
• Niranjan Sardesai,
  Sr. VP Research & Development
• Nancy Wysenski,
  Director
• Avtar S Dhillon,
  President & CEO
• Angel Cabrera,
  Director
• Austin W & Greenhouse David...,
  10% owner
• Dietmar P Rabussay,
  V.P. Research & Development
• George F. Iii Mc Hugh,
  Vice President, Operations
• Eugene A Larson,
  Director
• Felix Theeuwes,
  Director
• Robert S Goodenew,
  V.P. Corporate Development
• Michael Fons,
  VP, Corporate Development
• Kevin Rassas,
  Sr. VP Business Development
• Cheryl Jo White,
  Chief Medical Officer
• Tee Khiang Ng,
  Director
• Robert William Rieder,
  Director
• James L Heppell,
  Director
• David J Williams,
  Director
• Punit Dhillon,
  VP, Finance & Operations
• Riaz Amirali Bandali,
  Director
• Stephen Rietiker,
  Director
• Beng Lee Gan,
  Director
• Tazdin Esmail,
  Director
• Keith H Wells,
  Director
• Chin Cheong Chong,
  Director
• Roger D Dansey,
  Director
• Michael John Sumner,
  Chief Medical Officer